|Position||Trades||Duration||Win rate||Win/loss||Avg win||Avg loss||Return|
|Position||Trades||Duration||Win Rate||Win/Loss||Avg Win||Avg Loss||Return|
COMMODITY CHANNEL INDEX
Trading: HOLD @ $1.8
Signal Strength: MEDIUM
Mesoblast (ASX:MSB) current trading has maintained the Commodity Channel Index to oversold status and signalled the continuation of the bullish trading conditions. Currently, the CCI is 52. The bullish signal has been active for 0 day. During the quarter, the lowest CCI value was -183.
Indicator can be used in isolation or in additional to another technical indicator to confirmation for trading entry. Indicator can be applied to the short/medium term timeframe, but the best results are obtained with larger cyclical swings in-line with the trend direction. This accumulation / distribution oscillator can provide guidance on the money flow direction from the companies recent trading.
The Commodity Channel Index indicator takes a security’s change in price and compares that to its average change in price. CCIs calculation produces positive and negative values that oscillate above and below a Zero Line. Typically a value of 100 is identified as overbought and a reading of -100 is identified as being oversold.
Calculation: 20 Period CCI:
1) CCI = (Typical Price - 20 Period SMA of TP) / (.015 x Mean Deviation);
2) Typical Price (TP) = (High + Low + Close)/3;
PROFILE: Mesoblast (MSB.AX)
Stock Exchange: ASX
Ticker Codes: | MSB.AX | ASX:MSB |
Mesoblast Limited develops cell-based medicines. The company has leveraged its proprietary technology platform based on mesenchymal lineage adult stem cells to establish a portfolio of late-stage product candidates. Its allogeneic cell product candidates target advanced stages of diseases with high and unmet medical needs, including cardiovascular conditions, immunologic and inflammatory conditions, orthopedic disorders, and oncology and hematology conditions. The company's products under the Phase III clinical trials include MPC-150-IM for chronic and end-stage heart failure; MPC-06-ID for chronic low back pain; and MSC-100-IV for acute graft versus host disease in children. It is also developing MPC-300-IV that is in Phase II clinical trials for the treatment of biologic refractory rheumatoid arthritis, and diabetic kidney diseases and type 2 diabetes. The company has a collaboration agreement with JCR Pharmaceuticals Co., Ltd. It has operations in the United States, Australia, Singapore, and Switzerland. Mesoblast Limited was founded in 2004 and is headquartered in Melbourne, Australia.
|EMH European Metals Holdings||0.36||12.5||74,674||135||BULLISH|
|GGG Greenland Minerals||0.12||9.1||3,783,020||265||BULLISH|
|TNG Tennant Creek Gold||0.1||6.5||1,027,849||229||BULLISH|
|SYR Syrah Resources||0.49||5.4||4,913,585||136||BULLISH|
|AEF Australian Ethical Investments||3.21||5.2||113,550||136||BULLISH|
|SPL Starpharma Holdings||1.28||4.9||2,761,003||188||BULLISH|
|SWM Seven West Media||0.48||4.3||6,815,578||167||BULLISH|